MediWound CEO to Discuss Strategy at H.C. Wainwright Conference
Event summary
- MediWound CEO Ofer Gonen to participate in fireside chat on September 14, 2026.
- Event part of H.C. Wainwright 28th Annual Global Investment Conference in New York.
- Live webcast available via MediWound’s investor relations page.
- Company focuses on enzymatic therapeutics for tissue repair, with FDA-approved NexoBrid® and late-stage EscharEx® in pipeline.
The big picture
MediWound’s participation in the H.C. Wainwright conference underscores its push to highlight its enzymatic therapeutic pipeline amid a competitive landscape in wound care. The company’s focus on non-surgical solutions positions it in a growing segment of the biotech industry, where chronic wound management represents a significant unmet need. Success in this space could drive revenue growth and market differentiation.
What we're watching
- Pipeline Progress
- Whether EscharEx® can secure regulatory approval and become a new standard in chronic wound management.
- Market Expansion
- The pace at which MediWound can expand NexoBrid®’s market reach beyond current regions.
- Investor Sentiment
- How the fireside chat impacts investor confidence in MediWound’s long-term strategy.
Related topics